For Immediate Release:
NEWTOWN, PA — The Bracken Group (“Bracken”) today announced the addition of three senior experts to its Consulting team: Bernard J. Dardzinski, PhD; Darren Leva, MBS; and Ovid Trifan, MD, PhD. Their appointments expand Bracken’s scientific, clinical, and commercialization capabilities across biomedical imaging and quantitative methods, corporate development and M&A, and oncology drug development.
These additions reinforce Bracken’s role as an integrated, judgment-led partner for life-sciences organizations navigating increasingly complex scientific, regulatory, and commercial decisions.
Bernard J. Dardzinski, PhD – Biomedical Imaging, Quantitative Methods & Translational Science
Dr. Bernard (“Bernie”) Dardzinski is a biomedical imaging scientist and engineer with deep expertise in quantitative MRI, PET, and CT. He has led large-scale translational imaging programs, managed multimillion-dollar research portfolios, and authored more than 100 peer reviewed publications. He has held senior roles at the NIH, Uniformed Services University, The Children’s Hospital of Philadelphia, Merck, and Cincinnati Children’s Hospital delivering extensive experience in imaging strategy, biomarker qualification, and quantitative-method development.
Darren Leva, MBS – Commercial Strategy, Corporate Development & M&A
Darren Leva brings more than 22 years of experience in business development, corporate development, strategic partnerships, and M&A across biotechnology, pharmaceutical, and services organizations. He has led over 200 transactions and supported the raising of more than US$100 million in capital. An experienced entrepreneur, he has founded five companies and launched multiple ventures within larger organizations, advising companies as they scale and execute complex transactions.
Ovid Trifan, MD, PhD – Oncology Drug Development, Clinical Strategy & Translational Leadership
Dr. Ovid Trifan is an executive-level clinician-scientist with more than 20 years of experience in oncology drug development. He has held senior leadership roles at Bristol Myers Squibb, Johnson & Johnson, and Onyx Pharmaceuticals, contributing to teams that achieved approvals for therapies including cetuximab, sorafenib, ixabepilone, regorafenib, and necitumumab. Most recently, he has served as Chief Medical Officer for multiple oncology-focused biotech companies, leading clinical development, regulatory strategy, and investor engagement.
Executive Commentary
“Bernie, Darren, and Ovid join Bracken at a time of significant momentum,” said Colin G. Miller, PhD, CEO of The Bracken Group. “As our clients face increasingly complex scientific, regulatory, and commercial decisions, we continue to invest in senior-level expertise. Their combined experience significantly strengthens Bracken’s position as an integrated partner for life-sciences organizations navigating high-stakes decisions.”
About Bracken
Bracken provides integrated consulting, regulatory, analytics, marketing, and sales-enablement solutions to life-sciences and digital-health organizations. Bracken’s multidisciplinary teams combine senior-level expertise with scientific rigor and strategic insight to help organizations make confident decisions and deliver durable outcomes.
Contact us today to learn more about our services and working directly with Bracken’s team of expert consultants. Website: www.thebrackengroup.com.
Media Contact
Nurcan Tosun
ntosun@thebrackengroup.com
+1 215 648 1208